0:00
12:34
Annaka Haynes is a nursing student who has had Cystic Fibrosis since she was 6 weeks old. Trikafta developed by Vertex Pharmaceuticals was first approved by the FDA on October 21, 2019. This treatment is a triple combination regimen for cystic fibrosis patients starting at ages 2 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation in the CFTR gene that is responsive to Trikafta based on in vitro data.
Mais episódios de "The exhale podcast, brought to you by Vitalograph"
Não percas um episódio de “The exhale podcast, brought to you by Vitalograph” e subscrevê-lo na aplicação GetPodcast.